Eikon Therapeutics has raised $381 million from its IPO, at the top end of its expectations, in another sign of a pickup in appetite for new biotech listings on the Nasdaq. The South San Francisco ...

Biotechnology companies going public this week are signaling a resurgence for initial public offerings and venture-capital investment in the sector this year. Biotechs Eikon Therapeutics and ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon Therapeutics increased the ...

Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...

Shares of Eikon Therapeutics are set to begin trading Thursday after the clinical-stage biopharmaceutical company's upsized initial public offering was priced at the top of expectations. Eikon late ...

Eikon Therapeutics is heading to the Nasdaq this morning with an upsized $381 million IPO in a further sign of the renewed appeal of the public markets. The oncology biotech will offer 21.2 million ...

Feb 5 (Reuters) - Drug developer Eikon Therapeutics, headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in ‌their Nasdaq ...

After announcing plans to go public at the top of the year, Eikon Therapeutics has now revealed the proceeds it hopes to pull in from its initial stock offering: $273.5 million. The oncology biotech ...

Eikon Therapeutics, former MSD head of R&D Roger Perlmutter's new project, is hoping to raise up to $318 million from a Nasdaq listing, in another signal of building confidence in the biopharma sector ...

Jan 28 (Reuters) - Drug developer Eikon ‍Therapeutics said on Wednesday it was targeting a valuation of up to $908.2 ‌million in its U.S. initial public offering, as ‌biotech listings make a comeback.